TP53 and prostate cancer: As expected of a molecule that both activates PP2A and inhibits KPNB1, SH-BC-893 reduced nuclear levels of MYC in mPCE, MYC-CaP, LNCaP, and 22Rv1 prostate cancer cell lines and autochthonous tumors from pDKO mice lacking PTEN and p53 in the prostate (Fig. 3B–D,F; Appendix Fig. S8A–C).